KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Adaptive Biotechnologies (ADPT) Gross Profit (2018 - 2025)

Adaptive Biotechnologies (ADPT) has disclosed Gross Profit for 8 consecutive years, with $30.2 million as the latest value for Q4 2025.

  • Quarterly Gross Profit rose 2.83% to $30.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $182.4 million through Dec 2025, up 77.77% year-over-year, with the annual reading at $182.4 million for FY2025, 70.67% up from the prior year.
  • Gross Profit hit $30.2 million in Q4 2025 for Adaptive Biotechnologies, down from $75.8 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $75.8 million in Q3 2025 to a low of -$22.6 million in Q4 2021.
  • Historically, Gross Profit has averaged $24.3 million across 5 years, with a median of $25.9 million in 2022.
  • Biggest five-year swings in Gross Profit: plummeted 294.07% in 2021 and later soared 270.91% in 2022.
  • Year by year, Gross Profit stood at -$22.6 million in 2021, then skyrocketed by 270.91% to $38.6 million in 2022, then crashed by 65.96% to $13.1 million in 2023, then soared by 123.82% to $29.4 million in 2024, then increased by 2.83% to $30.2 million in 2025.
  • Business Quant data shows Gross Profit for ADPT at $30.2 million in Q4 2025, $75.8 million in Q3 2025, and $40.9 million in Q2 2025.